A novel, non-opioid pain drug candidate originating from research at the State University of New York at Stony Brook has reached a significant milestone.
A new therapeutic approach to halting the spread of prostate cancer developed by a Stony Brook University-led research team has garnered a new five-year grant from the National Cancer Institute (NCI), totaling $4.2...